Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 25,409

Document Document Title
WO/2017/181857A1
A composition for fat reduction and liver protection, a preparation method thereof, and a pharmaceutical product comprising same. The composition comprises: Radix Astragali, Radix Puerariae, and Cortex Mori. The mass ratio of Radix Astra...  
WO/2017/183028A1
The present invention provides compositions and methods for treating fibromyalgia syndrome (FMS). Specifically, the present invention provides anti eotaxin-2 antibodies for treating FMS.  
WO/2017/178856A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or limit development of neuromuscular diseases, including motor neuron diseases like amyotrophic lateral sclerosis.  
WO/2017/181014A1
The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from dystroph...  
WO/2017/179225A1
Provided is a composition which can effectively suppress or improve physical hypofunction observed with age or physical dysfunction occurring with age, or mental hypofunction observed with age or mental dysfunction occurring with age, sa...  
WO/2017/181015A1
The invention provides for recombinant AAV vectors comprising a miniaturized human micro-dystrophin gene and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.  
WO/2017/152090A3
The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes adm...  
WO/2017/180976A1
Described herein are recombinant AAV vectors comprising a polynucleotide sequence comprising β-sarcoglycan and methods of using the recombinant vectors to reduce or prevent fibrosis in a mammalian subject suffering from a muscular dystr...  
WO/2017/177945A1
Uses of a poria cocos extract, a tumulosic acid and/or a pharmaceutically acceptable salt of the tumulosic acid in the preparation of a drug or food, and the drug or the food is used for protecting muscles. The drug is especially used fo...  
WO/2017/178315A1
This invention relates to the use of a composition comprising a bacterium of the genus Bifidobacterium, particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis (strain) 420 (B420), and one or more prebi...  
WO/2017/179707A1
The present invention provides a novel combination for improving frailty or a novel combination for suppressing reduction in skeletal muscle mass. More specifically, the present invention provides a combination for improving frailty or a...  
WO/2017/175181A1
The present invention relates to the quantification of various soluble proteins, including angiogenin in aqueous humor and plasma of patients with AMD. The invention further describes the role of angiogenin in the pathogenesis, progressi...  
WO/2017/170926A1
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...  
WO/2017/173234A1
A method for treating a subject suffering from a motor neuron degenerative disorder is provided herein, the method including: administering to the subject one or more modified adeno-associated virus (AAV) gene delivery vectors packaging ...  
WO/2017/170924A1
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...  
WO/2017/170830A1
Provided is a compound having an MAGL-inhibiting effect, and anticipated to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, amy...  
WO/2017/098173A3
The invention relates to the field of medicine. More specifically, the invention relates to the use of compounds, on a patient, in order to prevent and/or treat myopathy, typically muscular dystrophy or cardiomyopathy, or a traumatic inj...  
WO/2017/163076A1
The invention relates to inhibitors of CDK12 (cyclin-dependent kinase 12), and there use in the treatment or prevention of a disorder in a subject caused by the generation of repeat expansion transcripts.  
WO/2017/162870A1
Methods for improving active movement capacity in a subject experiencing muscle impaired or abnormal activity, and software products and computer systems for implementing such methods. A subject having impaired active movement capacity i...  
WO/2017/077516A3
The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cance...  
WO/2017/158190A1
The present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, for the treatment of a disease selected fr...  
WO/2017/159380A1
The purpose of the present invention is to provide a method for producing an upper motor neuron from a pluripotent stem cell, and a pluripotent stem cell which can be converted into an upper motor neuron. This method comprises a step for...  
WO/2017/152744A1
The present invention provides a specific protein composition and a method for using the same. The composition is mainly a mixture of human rabies immunoglobulin (HRIG) and human tetanus immunoglobulin (HTIG), wherein the HRIG has an ant...  
WO/2017/150477A1
The purpose of the present invention is to provide a compound having an excellent JAK1-inhibiting activity. The compound according to the present invention has a JAK1-inhibiting activity, and therefore has an immunesuppressing effect, an...  
WO/2017/150228A1
The present invention addresses the problem of providing an efficacious means against muscle atrophy. Provided is a muscle atrophy inhibitor that comprises, as active ingredient(s): (1) one or more proteins selected from the group consis...  
WO/2017/147505A1
Provided are methods of treating muscle and liver disorders, and for increasing mitochondrial mass and/or functionality in a mammalian myocyte and/or hepatocyte.  
WO/2017/144977A1
The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.  
WO/2017/146053A1
Provided are: pharmaceutical composition particles and an orally disintegrating tablet including the same which are capable of achieving both the masking of unpalatable taste and an improvement in elution properties; and a method for pro...  
WO/2017/142054A1
Provided is an artificial nucleoside or an artificial nucleotide which can constitute an artificial oligonucleotide having excellent nuclease resistance. An artificial nucleoside or an artificial nucleotide, which is a compound represent...  
WO/2017/141911A1
The present invention relates to (2E)-N-[2-(dimethylamino)ethyl]-2-hexadecenamide, 2-(diethylamino)ethyl (2E)-2-hexadecenoate, or pharmaceutically acceptable salts thereof. In addition to activating signal transmission via the MAP kinase...  
WO/2017/130151A1
The present invention relates to nucleotides, analogs of mRNA 5'-end (cap) containing sulfur atom at the position 5' of 7-methylguanosine nucleoside. The disclosed compounds are recognized (bound and non-hydrolyzed) by DcpS enzyme (Decap...  
WO/2017/130190A1
This invention provides a novel formulation for effective delivery of a pharmaceutically active ingredient such as a peptide possessing neuroprotective activity. Also provided are methods for treating pertinent clinical implications such...  
WO/2017/131149A1
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity makes it possible to obtain a therapeutic agent for S1P5-me...  
WO/2017/132410A1
The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disc...  
WO/2017/131169A1
[Problem] The purpose of the invention is to provide a drug useful in the prophylaxis or treatment of muscle damage. [Solution] The invention relates to a novel pharmaceutical use of an extract from inflamed tissue inoculated with vaccin...  
WO/2017/126645A1
The purpose of the present invention is to provide a composition for inhibiting the migration of endotoxin into blood. According to the present invention, a composition for inhibiting the migration of endotoxin into blood is provided, wh...  
WO/2017/121333A1
Disclosed is a use of a Cistanche tubulosa extract, isoacteoside and/or a pharmaceutically acceptable salt of isoacteoside for the preparation of a drug or a food, wherein the drug or food is used to protect muscles. The drug is especial...  
WO/2017/118968A1
Novel aminoglycosides, represented by Formulae (I), (Ia), (III) and (IIIa), as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical composition...  
WO/2017/119476A1
Provided are: a composition for preventing neurological diseases; use of a material for preventing neurological diseases; and a method for preventing neurological diseases. It has been discovered that a heat-treated product of an animal/...  
WO/2017/113268A1
The present invention relates to a compound for treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and an application of the compound. The invention discloses a compound suppressing a toxicity induced by an rG...  
WO/2017/115789A1
Provided are compositions for recovering and/or ameliorating deterioration of physiological functions due to aging. A cell overexpressing GDF6 protein or an miR-17 family member. A composition for treating aging-related symptoms, said co...  
WO/2017/114339A1
Microencapsulation of β-alanine uses β-alanine as a core material and a mixture of a wall material and an additive as a release material. The additive comprises: a fatty acid-based saturated or unsaturated fatty acid glyceride containi...  
WO/2017/108419A1
Neuregulin-1 (NRG1) or a fragment thereof or vitamin B12 for use in maintaining or increasing muscle function and/or mass in an ageing subject, and/or substantially preventing or reducing muscle wasting in an ageing subject.  
WO/2017/111166A1
According to the present invention, a drug for treating an intracellular TDP-43 content-related disease is developed and provided . In the binding of TDP-43 to a specific mt-tRNA, the binding sites of the respective substances are identi...  
WO/2017/109494A1
The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to fo...  
WO/2017/110705A1
The present invention addresses the problem of developing a drug capable of regrowing synapses, which have been damaged and lost due to a neurodegenerative disease, to thereby provide a medicinal composition for preventing or treating a ...  
WO/2017/106354A1
Compositions and methods useful in treating spinal muscular atrophy are provided. The compositions comprise a recombinant adeno-associated viral vector containing an AAV capsid, e.g., AAVrh.10 capsid, and nucleic acid sequences encoding ...  
WO/2017/101858A1
Disclosed is a method for preparing an extended release dosage form comprising cyclobenzaprine hydrochloride as a main component. The method comprises the following steps: mixing the main component with excipients such as magnesium stear...  
WO/2017/101887A1
A healthcare pharmaceutical preparation having magnesium supplementation and anti-oxidation effects, and a preparation method for the healthcare pharmaceutical preparation. The healthcare pharmaceutical preparation comprises a main effec...  
WO/2017/104180A1
The present invention addresses the problem of providing a composition for enhancing: knee-joint-function improving effects obtained through resistance training without using a training apparatus; and skeletal-muscle-function reinforceme...  

Matches 351 - 400 out of 25,409